Make Informed Investment Decisions with Affordable Access to Experts
What impact could an approval of Opdivo in Hodgkin's Lymphoma data do to the current treatment options, specifically Adcetris?Ticker(s): SGEN, BMY
Name: Dr Robert Soiffer - MD
Institution: Dana Farber Cancer Institute
- Chief of the Division of Hematologic Malignancies and co-director of the Adult Stem Cell Transplantation Program
- Chairman of the Center for International Blood and Marrow Transplant Research advisory committee and has served as vice president (2006), president (2007), and immediate past president (2008) of the American Society of Blood and Marrow Transplantation.
- Authored a number of articles in peer reviewed journal and member of several professional organizations
Please describe your background treating Hodgkin's Lymphoma patients. How many do you currently care for?
Please compare and contrast the experience you have treating patients with Adcetris and the what we know currently about Opdivo's experience in HL.Added By: joe_mccann
How does your real world experience with Adcetris compare to the label? Are there ways that doctors and patients are mitigating some of these side effects?
How would you compare the side effect profiles of Opdivo and Adcetris based on what we currently know?
If Opdivo is able to replicate the data published in the NEJM and presented at ASH (87% response rate for Treatment of Relapsed or Refractory Hodgkins Lymphoma) what role do you see for Adcetris going forward? (assuming Opdivo is approved)
Given the age of empowerment by the internet of the public, how do you expect the HL market to fall after Opdivo is available....will 1st line and 2nd line and maintenance see a different split?Added By: usercdb8aa0e
How do elderly/frail handle the tox from Adcetris and how many are unable to get full cycles?Added By: usercdb8aa0e
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.